Compare ARK Space & Defense Innovation ETF (ARKX) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Space & Defense Innovation ETF vs TransMedics Group Inc — how do they compare? ARK Space & Defense Innovation ETF trades at $34.7, while TransMedics Group Inc trades at $87.08 (market cap $3.10B). The key difference: ARK Space & Defense Innovation ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| ARKX | TMDX | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $37.74 | $150.42 |
52-Week Low | $25.46 | $61.99 |
Market Cap | — | $3.10B |
Enterprise Value | — | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARK Space & Defense Innovation ETF (ARKX) trades at $34.8, up 1.13% today, with a bullish technical signal driven by strong moving average alignment. The ETF focuses on space economy exposure, including holdings like SpaceX (8.31%) and Rocket Lab (6.27%), benefiting from growing commercial and defense space investments. Recent news highlights competition with other space ETFs and the impact of SpaceX's IPO on the sector.
Outlook remains positive due to thematic tailwinds in space innovation, but high volatility and stretched valuations in key holdings pose risks. Investors gain diversified access to a high-growth theme, though expense ratios and sector concentration require careful consideration amid market fluctuations.
TransMedics Group (TMDX) trades at $87.42, down 1.12% on the day, with a bullish technical outlook from moving averages but bearish oscillators signaling potential overbought conditions. The company reported mixed Q2 2026 results, missing earnings estimates with EPS of $0.44 versus $0.50 expected, while revenue growth remains robust. Recent news highlights an ongoing investigation into fiduciary duties by directors, adding uncertainty.
The stock presents a cautious opportunity with strong analyst support (69% buy ratings) and a consensus price target of $99.57, implying upside, but risks include earnings volatility, margin pressures, and legal scrutiny. Fundamentals show solid profitability with a 22.69% net margin, though valuation multiples like P/E of 23.15 suggest premium pricing relative to historical norms.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Space & Defense Innovation ETF
ARKX is an actively managed ETF that invests in companies leading space exploration and defense innovation. It focuses on orbital and sub-orbital aerospace, reusable rockets, and enabling technologies like AI, robotics, and satellite systems.
Read more on ARKX →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
